Observational Study to Assess the Effect of Iluvien® in DME Patients Insufficiently Responsive to Available Therapies
NCT ID: NCT02080091
Last Updated: 2015-08-26
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
25 participants
OBSERVATIONAL
2013-12-31
2015-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Pilot Study on the Effect and Safety of Iluvien® in Chronic Diabetic Macular Edema Patients
NCT02359526
A Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME)
NCT04469595
Pharmacokinetic and Efficacy Study of Fluocinolone Acetonide Inserts in Patients With Diabetic Macular Edema
NCT00490815
Fluocinolone Acetonide Implant Compared to Sham Injection in Patients With Diabetic Macular Edema
NCT00344968
Fluocinolone Acetonide in Diabetic Macular Edema (FAME) Extension Study
NCT01304706
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Chronic DME
Patients with vision impairment associated with chronic diabetic macular edema (DME)
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* DME based on physician's clinical evaluation and demonstrated on fundus photographs and/or optical coherence tomography (OCT);
* Vision impairment associated with DME
* Prior treatment with available therapies for DME; and
* Patients considered by the physician insufficiently responsive to available therapies
Exclusion Criteria
* The presence of pre-existing glaucoma
* Active or suspected ocular or periocular infection
* The patient is hypersensitive to the active agent or to one of the excipients
* Elevated IOP
* Pregnancy or breastfeeding
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alimera Sciences
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Professor Helmut Hoeh, MD
Role: STUDY_CHAIR
Dietrich-Bonhoeffer-Klinikum
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Neubrandenburg, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
M-01-13-003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.